Effects of non-toxic and toxic concentrations of phenytoin on monoamines levels in rat brain

Epilepsy Research

Volumn 28, Issue 2, 1997, Pages 155-163

  Okada, Motohiro ^a   Kawata, Yuko ^a   Kiryu, Kazuhiro ^a   Mizuno, Kazuhisa ^a   Wada, Kazumaru ^a   Inomata, Hitoshi ^a   Tasaki, Hiroichi ^a   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Dopamine; Epilepsy; Microdialysis; Paradoxical Intoxication; Phenytoin; Serotonin

Indexed keywords

ANTICONVULSIVE AGENT; BRAIN MONOAMINE; DOPAMINE; PHENYTOIN; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; GRAND MAL SEIZURE; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MONOAMINERGIC SYSTEM; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICRODIALYSIS; PHENYTOIN; RATS; RATS, WISTAR;

EID: 0030741057     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(97)00043-0     Document Type: Article

References (42)

1. Adell A, Carceller A, Artigas F. In vivo brain dialysis study of the somatodendritic release of serotonin in the raphe nuclei of the rat: Effects of 8-hydroxy-2(di-n-propylamino)tetralin. J Neurochem 1993;60:1673-81.
2. Azzaro AJ, Gutrecht JA. Characteristics of the inhibitory action of diphenylhydantoin on brain monoamine oxidase. Neurology 1975;25:378.
3. Azzaaro AJ, Gutrecht JA, Smith DJ. Effect of diphenylhydantoin on the uptake and catabolism of 1-(3H)norepinephrine in vitro in rat cerebral cortex tissue. Biochem Pharm 1973;22:2719-29.
4. Bruni J, Phenyloin Toxicity. In: Levy RK, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs, 4th ed. New York:Raven Press, 1995:345-350.
5. Butcher SP, Fairbrother LS, Kelly JS, Arbuthnott GW. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 1990;55:981-8.
6. DeLorenzo RL. Phenytoin Mechanisms of action. In: Levy RK, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs, 4th ed. New York:Raven Press, 1995:271-282.
7. Glowinski J, Iversen L. Regional studies of catecholamines in the rat brain. J Neurochem 1966;13:665-9.
8. Hadfield MG. Uptake and binding of catecholanine; effects of diphenylhidantoin and a new mechanism of action. Arch Neurol 1972;26:78-84.
9. Heeringa MJ, Abercrombie ED. Biochemistry of somatodendric dopamine release in substantia nigra: An in vivo comparison with striatal dopamine release. J Neurochem 1995;65:192-200.
10. Juergens U. Simultaneous determination of zonisamide and nine other anti-epileptic drugs and metabolites in serum. J Chromatogr 1987;385:233-40.
11. Kaneko S, Hirano T, Kondo T, Otani K, Fukushima Y, Hishida R, Matsunaga M. Antiepileptic drug phenytoin potentiates GABA in the rat cuneate nucleus. Jpn J Psychiatr Neurol 1988;42:643-5.
12. Kaneko S, Okada M, Hirano T, Kondo T, Otani K, Fukushima Y. Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine dose not antagonize adenosine effect in vibo: mechanisms of blockade of seizure spread. Jpn J Psychiatr Neurol 1993;47:371-3.
13. Kato T, Otsu Y, Furune Y, Yamamoto T. Diffent effects of L-, N and T-type calcium channel blockers on striatal dopamine release measured by microdialysis in freely moving rats. Neurochemistry 1992;21:99-107.
14. Levy LL, Fenichel GM. Diphenylhydantoin activated seizures. Neurology 1965;15:716-22.
15. MacdonaldRL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36 Suppl. V:S2-12.
16. Masuda Y, Utsui Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M. Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benziosoxazole (AD810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals. Epilepsia 1979;20:623-33.
17. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage limitation of high frequency repetitive firing of action potential of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;237:1001-11.
18. Merritt HH, Putnam TJ. A new series of anticonvulsant drugs tested by experiments on animals. Arch Neurol Psychiatr 1938;39:1003-5.
19. Meshkibaf MK, Subhash MN, Lakshmana KM, Rao BS. Effect of chronic administration of phenytoin on regional monoamine levels in rat brain. Neurochem Res 1995;20:773-8.
20. Mizuno K, Okada M, Kaneko S, Hirano T, Tokinaga N, Chiba T, Otani K, Fukushima Y. Effects of zonisamide, carbamazepine and valproate on monoamine metabolism in rat striatum and hippocampus. Jpn J Psychiatr Neurol 1994;48:406-8.
21. Moghaddam B, Bunney BS. Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J Neurochem 1989;53:652-4.
22. Nakahra D, Ozaki N, Kapoor V, Nagalsu T. The effect of uptake inhibitor on dopamine release from the nucleus of rats during self- or forced stimulation of the medial forebrain bundle: a microdialysis study. Neurosci Lett 1989;104:136-40.
23. 2+ dependent dopamine release. Epilepsy Res 1992;13:113-9.
24. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fubkushima Y. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995;22:193-205.
25. Okada M, Mizuno K, Ohuyama M, Kaneko S. Magnesium ion augmentation of inhibitory effects of adenosine on dopamine release in the rat striatum. Psychiatr Clin Neurosci 1996;50:147-56.
26. Okada M, Mizuno K, Kaneko S. Adenosine Al and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 1996;212:53-6.
27. Okada M, Kiryu K, Kawata Y, Mizuno K, Wada K, Tasaki H, Kaneko S. Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur J Pharmacol 1997;32:181-8.
28. Osorio I, Burnstine TH, Remler B, Manon-Espaillat R, Reed RC. Phenytoin-induced seizures: A paradoxical effect at toxic concentrations in epileptic patients. Epilepsia 1989;30:230-4.
29. Pani L, Kuzmin A, Diana M, De Montis G, Cessa GL, Rossetti ZL. Calcimn receptor antagonists modify cocaine effects in the central nervous system differently. Eur J Pharmacol 1990;190:217-21.
30. Paxinos G, Watson C, editors. The rat brain in stereotaxic coordinates, San Diego:Academic Press, 1986.
31. Putnam TJ, Merritt HH. Experimental determination of anticonvulsant properties of some phenyl derivatives. Science 1937;85:525-6.
32. 2+ channel currents in rat cerebellar granule neurons. J Neurosci 1995;15:2995-3012.
33. Snider SR, Snider RS. Phenytoin and cerebellar lesions. Similar effects on cerebral catecholamine metabolism. Arch Neurol 1977;34:162-7.
34. Sayer RJ, Brown AM, Schwindt PC, Crill WE. Calcium currents in acutely isolated human neocortical neurons. J Neurophysiol 1993;69:1596-606.
35. + channels. Mol Pharmacol 1993;43:946-55.
36. Troupin AS, Ojemann LM. Paradoxical intoxication - a complication of anticonvulsant administration. Epilepsia 1975;16:753-85.
37. Wakamori M, Kaneda M, Oyama Y, Akaike N. Effects of chlordiazopoxide and haloperidol on the voltage-dependent sodium current of isolated mammalian brain neurons. Brain Res 1989;494:374-8.
38. 2+ channels in supporting hippocampal synaptic transmission. Science 1994;264:107-11.
39. Weinberger J, Nichlas WJ, Berl S. Mechanism of action of anticonvulsants. Neurology 1976;26:162-6.
40. Westerink BHC, Damsma G, Rollema H, De Vries JB, Horn AS. Scope and limitation of in vivo brain dialysis: A comparison of its application to various neurotransmitter systems. Life Sci 1987;41:1763-76.
41. Westerink BHC, Hofsteede HM, Damsma G, De Vries JB. The significance of extracellular calcium for the release of dopamine, acetylcholine and amino acids in conscious rats, evaluated by brain microdialysis. Nauyn-Schmiedeberg's Arch Pharmacol 1988;337:373-8.
42. Wilder BJ. Phenytoin: Clinical Use. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs, 4th ed. New York:Raven Press, 1995:339-344.